Dechert acted as transaction counsel for Abivax’s €28 million capital increase. Abivax is a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer.
The proceeds of the capital increase, which leading biotech investors in Europe and the United States oversubscribed to without any discount to the last closing price, will be used mainly to fund late-stage clinical trials of the company's lead product, ABX464, in the treatment of inflammatory diseases and of COVID-19.
Bryan, Garnier & Co. Limited acted as the sole global coordinator and sole bookrunner.
The international Dechert team advising Abivax included:
- In Paris: Alain Decombe, partner, with Vianney Toulouse and Benhouda Derradji, associates;
- In London: Patrick Lyons, partner, with Jennifer Rees, senior associate.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
